OPTIMA

– Our Vision –

Our vision is that every patient should have access to the most up-to-date individualised treatments and to innovative therapies.
By strengthening shared decision-making based on dynamic computer-interpretable guidelines (CIGs), innovative broad data access and AI-driven technology and tools, we envision revolutionizing oncology care in Europe.

What are
we aiming for?

Implement a federated and centralised access to a vast network of European data providers to help answer the highest priority research questions in prostate, breast and lung cancer, especially where current existing evidence underpinning clinical practice guidelines is weak or not covered at all in current guidelines.

In parallel, comprehensive decision support toolsets will be made available to fill the guidelines gaps and better support shared decision making by clinicians and patients. The toolsets will be based on national and international guidelines with approved regular updates of guideline recommendations underpinned by evidence from advanced statistical analysis and AI.

OPTIMA

Which challenges
are addressed?

This content will be disabled.

Add content for this tabs in the next section.

Row for Tabs (sort to change the order/target tabs)

 content edit below

 content edit below

content edit below

content edit below

Challenges for patients

For patients, the increasing complexity of diagnostics and treatments available are difficult to comprehend. This poses a significant barrier to patients receiving optimal individualised treatment and care within a shared decision-making framework with their clinician.

Challenges for clinicians

For clinicians, the tremendous volume of rapidly changing information on new diagnostic tests, novel treatments, and guidelines poses a formidable challenge when deciding the optimal treatment for their patients.

Challenges for pharmaceutical companies & regulators

For pharmaceutical companies and regulators, understanding real-world treatment outcomes of novel compounds outside of well controlled randomised controlled trials (RCTs) has become a vital component of drug development, regulatory approval, access to market, and post-market assessment.

Challenges for healthcare payers

For healthcare payers, the scarcity of reliable and complete real-world evidence on the effectiveness and real-world safety of treatments complementary to RCTs data prevents real-time decision-making and effective management of resources.

Challenges for healthcare ecosystems

For healthcare ecosystems, experiencing a shift from organisation-focused to patient-focused healthcare has triggered the implementation of a new and technology-enabled healthcare ecosystem. The digital revolution challenges the status quo and requires new infrastructures in place to ensure innovative care models can be implemented into routine clinical practice.

Principles & Key Objectives

Availability to all relevant stakeholders

Establish a data catalogue by gathering and harmonising large-scale structured and unstructured real-world datasets from European EHR and other types of real-world data.

Trust and Acceptability to stakeholders such as physicians and patients

Develop a scalable and regularly updated guideline decision-support toolset as part of the platform for the three prioritised indications prostate, breast, and lung cancer.

Real added Value for all stakeholders

  • Drive new knowledge generation through advanced analytics and AI-models
  • Ensure the sustainability of OPTIMA’s platform by supporting business models based on commercial users

Sustainability in terms of operational capacity beyond the duration of the action

Develop and implement a secure, sustainable, valuable, and interoperable platform to host harmonization tools, federated learning tools and AI algorithms, and guideline-based decision support tools.

Availability to all relevant stakeholders

Establish a data catalogue by gathering and harmonising large-scale structured and unstructured real-world datasets from European EHR and other types of real-world data.

Trust and Acceptability to stakeholders such as physicians and patients

Develop a scalable and regularly updated guideline decision-support toolset as part of the platform for the three prioritised indications prostate, breast, and lung cancer.

Sustainability in terms of operational capacity beyond the duration of the action

Develop and implement a secure, sustainable, valuable, and interoperable platform to host harmonization tools, federated learning tools and AI algorithms, and guideline-based decision support tools.

Real added Value for all stakeholders

  • Drive new knowledge generation through advanced analytics and AI-models
  • Ensure the sustainability of OPTIMA’s platform by supporting business models based on commercial users
et|icon_plus|L

Work Packages

Dedicated groups to
reach our goals.

Work Packages

Dedicated groups to
reach our goals.

Consortium Members

AbbvieAmgenARTTIC Innovation GmbHAssociation EISMBayer AGCASUS, Helmholtz-Zentrum Dresden – RossendorfEuropean Association of UrologyEuropean Cancer Patient CoalitionEuropean Institute of OncologyEuropean Lung FoundationEuropean Respiratory SocietyErasmus University Medical Center RotterdamGerman Cancer Society (DKG)GMV Soluciones Globales de Internet SAUHelios Klinikum Emil von BehringHoffman-La Roche AGInformation Technology for Translational Medicine
Ludwig-Maximilians-University MunichLund UniversityMaastricht UniversityOWKINPfizerQueen Mary University LondonSmartReportingThe Institut Universitari d’investigació en Atenció PrimàriaThe University Court of the University of AberdeenTTOPSTARTUniversita Vita-Salute San RaffaeleUniversity College London / University College London HospitalUniversity of TartuUniversity of Oxford – Centre for Statistics in MedicineUniversity of ViennaUppsala UniversityYdeal
mt|add_circle|

Tackling Cancer through Real World Data
and Artificial Intelligence